Pharmafile Logo
Pharmafocus logo
Advanced Search

Johnson & Johnson

Showing 15 posts of 132 posts found.

J&J continues to shed assets, with $2.1bn diabetes unit sale

June 13, 2018
Research and Development, Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

Just last week, Johnson & Johnson announced that it had received an offer from Fortive for its medical sterilisation unit, …

News

J&J looks to trim business with $2.8bn sale

June 7, 2018
Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

Johnson & Johnson continues to look at options to slim down its business, after having received an offer from Fortive …

News
onlinr

Celgene bring in new CFO to steady the ship

June 4, 2018
Medical Communications, Sales and Marketing Celgene, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …

News
jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

News
jj

J&J’s ketamine-based antidepressant showed mixed success at Phase 3

May 8, 2018
Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …

News

J&J’s ketamine nasal spray for depression continues to impress

April 16, 2018
Research and Development, Sales and Marketing Johnson & Johnson, Ketamine, biotech, drugs, pharma, pharmaceutical

New treatments for depression are few and far between; pharmaceutical companies have shied away from trying to develop new therapeutics …

News
kris-sterkens-23052017-hr-1

Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA

April 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, Kris Sterkens, pharma

Pharmafile.com sat down with Kris Sterkens, Company Group Chairman of Janssen’s EMEA operations to discuss nearly three decades at the …

Feature
shutterstock_274590824

J&J pays out $37m in damages over claims its talc contains asbestos

April 6, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, mesothelioma, ovarian cancer, pharma, talc

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …

News
dominic_caruso

J&J’s longest-standing CFO finally steps down

March 21, 2018
Medical Communications, Research and Development J&J, JJ, Johnson & Johnson, biotech, cfo, drugs, pharma, pharmaceutical

Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from …

News

FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer

February 9, 2018
Medical Communications, Sales and Marketing Cancer, FDA, J&J, JJ, Janssen, Johnson & Johnson, Zytiga, pharma

Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the …

News

Theravance seals potential $1bn deal with J&J

February 8, 2018
Sales and Marketing Johnson & Johnson, Theravance Biopharma, biotech, drugs, pharma, pharmaceutical

The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted …

News

J&J’s apalutamide shows strength in non-metastatic prostate cancer

February 7, 2018
Research and Development J&J, JJ, Johnson & Johnson, pharma, prostate cancer

Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide …

News
shutterstock_92671375

US court upholds ruling that J&J’s Remicade patent is invalid

January 24, 2018
Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …

News
jj_sign_on_wall

J&J withdraws controversial vaginal mesh from Australian market

January 23, 2018
Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, lawsuit, pharma, vaginal mesh

Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes

The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023